BioAdaptives

BioAdaptives Current Assets

The Current Assets of BioAdaptives (BDPT) as of Oct 25, 2026 is 211,901.00 USD. In the previous year, Current Assets was 259,085.00 USD — a change of -18.21% (lower).

Current Assets

211,901.00USD

YoY

-18.21%

Last updated:

Current Assets of BioAdaptives is 2025 211,901.00 USD. Current Assets of BioAdaptives was 2024 259,085.00 USD. It decreases by -18.21% lower compared to the previous year.

The BioAdaptives Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
110,059.00 USD
Jan 1, 2019
24,213.00 USD
Jan 1, 2020
18,846.00 USD
Jan 1, 2021
88,876.00 USD
Jan 1, 2022
34,324.00 USD
Jan 1, 2023
88,557.00 USD
Jan 1, 2024
259,085.00 USD
Jan 1, 2025
211,901.00 USD
The BioAdaptives Current Assets history
YEARCurrent AssetsYoY
211,901.00USD-18.21%
259,085.00USD+192.56%
88,557.00USD+158.00%
34,324.00USD-61.38%
88,876.00USD+371.59%
18,846.00USD-22.17%
24,213.00USD-78.00%
110,059.00USD+2,988.94%
3,563.00USD-97.57%
146,557.00USD+2,099.56%
6,663.00USD-90.67%
71,406.00USD-41.47%
122,009.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioAdaptives Stock analysis

What does BioAdaptives do? BioAdaptives, Inc. generates revenue through the sale of health and wellness products including dietary supplements, specialty food items, and devices that optimize bioelectromagnetic availability. The company markets PrimiCell and PrimiLive under a product agreement with Ferris Holding, Inc., targeting consumers seeking cognitive enhancement, fatigue reduction, and anti-aging solutions. PrimiTrim serves the weight control segment, while Equine Regen and Equine Regen Plus are in advanced testing for veterinary use. The firm also develops a dog product, expanding its wellness offerings across human and animal health markets. Ferris Holding, Inc. provides the intellectual property and products that BioAdaptives markets, including PrimiCell and PrimiLive, which are positioned for cognition, focus, and emotional wellness. The company's advanced-stage products Equine Regen and Equine Regen Plus cater to the veterinary segment, with PrimiTrim addressing weight management needs. BioAdaptives' product portfolio spans nutraceuticals, devices, and specialty foods designed to improve physical and emotional wellness across multiple consumer segments. BioAdaptives focuses on selling devices and nutraceuticals that target cognitive performance, fatigue reduction, and anti-aging, with PrimiCell and PrimiLive as key products under the Ferris agreement. The company's weight control solution PrimiTrim appeals to consumers seeking wellness through diet, while Equine Regen and Equine Regen Plus target animal health providers. The firm's development of a dog product further diversifies its offerings in the wellness market. BioAdaptives is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioAdaptives stock

Current Assets of BioAdaptives is 211,901.00 USD in 2025.

Current Assets of BioAdaptives changed from 259,085.00 USD to 211,901.00 USD, representing a -18.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets BioAdaptives since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's BioAdaptives historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioAdaptives

All Key Metrics — BioAdaptives